You are here: Industry Insights > Bevacizumab

News List

FDA Approves Atezolizumab, plus Bevacizumab for Unresectable Hepatocellular Carcinoma americanpharmaceuticalreview
June 11, 2020
The Food and Drug Administration (FDA) has approved atezolizumab in combination with bevacizumab (TECENTRIQ and AVASTIN, Genentech Inc.) for patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.
Biocon Biologics receives EU GMP Certification for multiple Biosimilars manufacturing facilities in expresspharma
May 20, 2020
These facilities are used for the manufacture of DS and DP for Biosimilars: Bevacizumab, Trastuzumab, Pegfilgrastim and secondary packaging of Insulin Glargine for EU markets.
COVID-19 clinical trials exhibit encouraging results: GlobalData expresspharma
May 18, 2020
Four multinational clinical trials that are planning to enrol the most subjects are investigating remdesivir, sarilumab and bevacizumab.
Lynparza, Bevacizumab Combination Approved for HRD-Positive Advanced Ovarian Cancer in the US americanpharmaceuticalreview
May 15, 2020
AstraZeneca and Merck announced that Lynparza (olaparib) in combination with bevacizumab has been approved in the US for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.
FDA Accepts BLA for Proposed Biosimilar Bevacizumab for Review americanpharmaceuticalreview
March 10, 2020
Mylan and Biocon announced the U.S. Food and Drug Administration (FDA) has accepted Mylan's Biologics License Application (BLA) for MYL-1402O, a proposed biosimilar to Avastin® (bevacizumab), for review under the 351(k) pathway.
Lynparza regulatory submission granted Priority Review in the US for 1st-line maintenance treatment with bevacizumab in advanced ovarian cancer worldpharmanews
January 16, 2020
AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced that a supplemental New Drug Application for Lynparza (olaparib) in combination with bevacizumab has been accepted and granted ...
Addition of Maintenance Olaparib Slows Advanced Ovarian Cancer drugs
December 19, 2019
Compared with placebo, the addition of olaparib to maintenance therapy with bevacizumab is associated with a significant progression-free survival benefit for patients with ...
AmEx Pharmacy Issues Voluntary Nationwide Recall for all Lots of Bevacizumab americanpharmaceuticalreview
September 05, 2019
AmEx Pharmacy has announces a voluntary recall of all Lots of Bevacizumab 1.25mg/0.05mL 31G Injectable and all Lots of Bevacizumab 2.5mg/0.1ml Normject TB Injectable...
Lynparza, Bevacizumab Trial Meets Primary Endpoint for Advanced Ovarian Cancer americanpharmaceuticalreview
August 19, 2019
AstraZeneca and Merck announced positive results from the Phase III PAOLA-1 trial in women with advanced ovarian cancer. The trial, in the 1st-line maintenance setting ...
Lynparza Phase III PAOLA-1 trial met primary endpoint as 1st-line maintenance treatment with bevacizumab for advanced ovarian cancer worldpharmanews
August 16, 2019
AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced positive results from the Phase III PAOLA-1 trial in women with advanced ovarian cancer.

Previous page 1 2 3 Next page